




Therapeutic discovery for pain

Daniela Salvemini, PhD

William Beaumont Professor and Chair Department of Pharmacology and Physiology Director, Institute for Translational Neuroscience

G protein-coupled receptors (GPCRs), the largest class of membrane proteins, represent the most druggable targets to make it to market

- There are 826 human GPCRs.
- ~350 non-olfactory GPCRs are considered druggable
- ~175 GPCRs are validated drug targets (Yang et al., 2020)
- The rapid increase in structural studies have yielded
 - 1,296 GPCR structures
 - 842 GPCR structure models
 - 743 refined models
- ~35% of all FDA-approved drugs target GPCRs (527 drugs) (Yang et al., 2020).
- Yet, there are ~120 orphan GPCRs whose endogenous ligands are still not known.
- Only a few FDA-approved drugs target orphan GPCRs.



Yang, D., et al. *Sig Transduct Target Ther*Pándy-Szekeres G., et al. *Nucleic Acids Res.*Hauser, A. et al., *Nat Rev Drug Discov*Sriram K, et al., *Mol Pharmacol.*

Targeting orphan GPCRs: breaking barriers to novel analgesic drug

